We are live on
!
Find out more
BM
Brandywine Managers Portfolio holdings
AUM
$170M
1-Year Est. Return
10.01%
This Fund
S&P 500
This Quarter
Est. Return
+27.54%
1 Year Est. Return
+10.01%
3 Year Est. Return
+53.1%
5 Year Est. Return
+7.42%
10 Year Est. Return
+248.69%
AUM
$91.3M
AUM Growth
+$32.1M
(+54%)
Cap. Flow
+$15.2M
Cap. Flow
% of AUM
16.59%
Top 10 Holdings %
Top 10 Hldgs %
80.45%
Holding
44
New
6
Increased
5
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI ACWI ETF
ACWI
|
+$7.02M |
| 2 |
UiPath
PATH
|
+$6.89M |
| 3 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
+$483K |
| 4 |
CrowdStrike
CRWD
|
+$250K |
| 5 |
Beam Therapeutics
BEAM
|
+$200K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
OLK
Olink Holding AB (publ) American Depositary Shares
OLK
|
+$201K |
| 2 |
Natera
NTRA
|
+$54.5K |
| 3 |
10x Genomics
TXG
|
+$49.4K |
| 4 |
Intuitive Surgical
ISRG
|
+$48.3K |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$44.3K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 52.71% |
| 2 | Healthcare | 10.9% |
| 3 | Consumer Staples | 1.14% |
| 4 | Financials | 0.83% |
| 5 | Consumer Discretionary | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Mobileye
MBLY
$7.76B
| $566K | 0.62% |
13,067
| – | – |
|
|
27
10x Genomics
TXG
$5.55B
| $564K | 0.62% |
10,073
-1,135
| -10% | -$49.4K |
|
28
Snowflake
SNOW
$93.2B
| $507K | 0.56% |
2,549
| – | – |
|
29
Structure Therapeutics
GPCR
$3.45B
| $489K | 0.54% |
12,007
+1,007
| +9% | +$57.7K |
|
30
Guardant Health
GH
$20.7B
| $387K | 0.42% |
14,303
-1,630
| -10% | -$42.8K |
|
|
SMAR
31
DELISTED
Smartsheet Inc.
SMAR
| $368K | 0.4% |
7,700
| – | – |
|
32
Relay Therapeutics
RLAY
$4.34B
| $350K | 0.38% |
31,807
| – | – |
|
33
Unity
U
$12.7B
| $340K | 0.37% |
8,327
| – | – |
|
34
Roblox
RBLX
$37B
| $331K | 0.36% |
7,241
| – | – |
|
35
AbCellera Biologics
ABCL
$1.97B
| $325K | 0.36% |
56,976
| – | – |
|
36
Prime Medicine
PRME
$565M
| $292K | 0.32% |
32,977
| – | – |
|
|
DOCU
37
DocuSign
DOCU
$10.1B
| $250K | 0.27% |
+4,211
| New | +$193K |
|
|
38
Beam Therapeutics
BEAM
$2.83B
| $220K | 0.24% |
+8,067
| New | +$200K |
|
39
SentinelOne
S
$6.71B
| $217K | 0.24% |
+7,900
| New | +$153K |
|
40
Denali Therapeutics
DNLI
$3.7B
| $206K | 0.23% |
+9,601
| New | +$190K |
|
41
Fulcrum Therapeutics
FULC
$243M
| $176K | 0.19% |
26,127
| – | – |
|
42
Seer Inc
SEER
$119M
| $86.4K | 0.09% |
+44,552
| New | +$79.2K |
|
|
OLK
43
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
| – | – |
-13,600
| Closed | -$201K |
|
|
CELL
44
DELISTED
PhenomeX Inc. Common Stock
CELL
| – | – |
-29,772
| Closed | -$29.7K |
|
Similar funds
CF
DBFM
CAS
FH
RWFS
RFO
DWM
AGC
Brandywine Managers's Q4 2023 Portfolio in Review
As of Q4 2023, Brandywine Managers held 44 positions worth $91.3M, up 54% from $59.3M the previous quarter. Its ten largest holdings account for 80% of the portfolio.
Brandywine Managers deployed $15.2M of net new capital in Q4 2023, opening 6 new positions and adding to 5 existing holdings. Its largest new stake was Morphic Holding, Inc. Common Stock: 20,286 shares worth $586K.
By sector, the portfolio is most concentrated in Technology at 53% of assets, up from 47% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was Natera, an estimated $54.5K trimmed.
- Brandywine Managers's largest Q4 2023 buy was Morphic Holding, Inc. Common Stock: 20,286 shares worth $586K.
- Brandywine Managers added most to iShares MSCI ACWI ETF in Q4 2023, an estimated $7.02M increase.
- Brandywine Managers's biggest Q4 2023 reduction was Natera, cutting an estimated $54.5K.
- Brandywine Managers fully exited Olink Holding AB (publ) American Depositary Shares in Q4 2023, selling an estimated $201K.
- Brandywine Managers's ten largest holdings make up 80% of its $91.3M portfolio in Q4 2023.
- Brandywine Managers opened 6 new positions and closed 2 in Q4 2023.
- Brandywine Managers's portfolio value rose 54% quarter-over-quarter to $91.3M.
Based on Brandywine Managers's 13F filing for Q4 2023, filed 14 Feb 2024.